---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-075016"
form_type: "8-K"
ticker: "GRML"
cik: "0001907223"
company_name: "Greenland Mines Ltd"
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:54:13.289215+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Klotho Neurosciences signs $250K manufacturing deal with AAVnerGene for KLTO-202 gene therapy

## Summary
- Initial fees of $250,000; additional fees tied to clinical trial stages plus 2% royalty on product revenue.
- Agreement covers manufacturing and development of KLTO-202 using AAVnerGene's AAVone platform technology.
- AAVnerGene's ATHENA tissue-targeting system aims to avoid liver homing and reduce inflammatory side effects.
- CEO states partnership expected to lower cost, increase purity, and accelerate time to clinic.

## SEC filing metadata
- accession: 0001213900-25-075016
- form_type: 8-K
- ticker: GRML
- cik: 0001907223
- company_name: Greenland Mines Ltd
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1907223/000121390025075016/0001213900-25-075016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1907223/000121390025075016/ea0252863-8k_klotho.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-075016
- JSON: https://secwatch.observer/filing/0001213900-25-075016.json
- Plain text: https://secwatch.observer/filing/0001213900-25-075016.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.